Chimerix — Investor Presentation (August 2024)
35 slides from Chimerix's investor presentation, Aug 13, 2024
Slide 1: Chimerix Corporate Presentation
Chimerix Corporate Presentation Aug 13, 2024
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking stateme
Slide 3: Investment highlights and key catalysts
3 Investment highlights and key catalysts Dordaviprone Ph 3 trial enrolling - interim OS data expected in third quarter 2025 First-Line H3 K27M-mutant diffuse glioma – The ACTION Study No approved therapies targeting H3 K27M diffuse glioma, an area of high unmet medical need First in class mecha
Slide 4: Deep pipeline across all development stages
4 Program Preclinical Phase 1 Phase 2 Registrational Regulatory Approval Deep pipeline across all development stages Dordaviprone (ONC201) H3 K27M-mutant glioma (orphan drug,1 fast track2 and rare pediatric disease designations3) IITs- signal finding, multiple oncology indications/combinations CMX52
Slide 5: Dordaviprone (ONC201) Phase 2 Data Analysis
Dordaviprone(ONC201) Phase 2 Data Analysis
Slide 6: Dordaviprone data suggests potential to address high unmet need
6 • H3 K27M mutation is predominantly found among diffuse midline gliomas (DMGs) in young adults and children • Frontline radiotherapy remains standard of care with transient benefit; resection often not feasible • DMGs harboring the H3 K27M mutation are WHO Grade IV; historically invariably lethal
Slide 7: Dordaviprone Phase 2 efficacy analysis
7 • Dordavirprone monotherapy exhibited durable, clinically meaningful efficacy in recurrent H3 K27M-mutant DMG - Overall Response Rate (ORR) of 30% (95% CI: 18 - 45%) by RANO HGG and/or LGG dual reader BICR - RANO-HGG criteria assessed by dual reader BICR • ORR 20% (95% CI: 10 – 34%) • Median Durat
Slide 8: Dordaviprone Ph 2 Efficacy Analysis by BICR in Recurrent H3 K27M-mutant DMG
8 • Strict selection criteria to ensure responses attributable to single agent treatment • RANO requires both confirmed radiographic response and other forms of clinical benefit (eg no increase in steroid utilization, no deterioration in performance status, et al) • Assessments done by dual reader b
Slide 9: Clinically meaningful and durable RANO-HGG responses
9 Clinically meaningful and durable RANO-HGG responses SPD=sum of products of perpendicular diameters (target enhancing lesions per BICR) Only patients with measurable target enhancing lesions by BICR at baseline and with post-baseline evaluations are included. Three patients did not have on-treatme
Slide 10: Dordaviprone safety
10 Clinical Pharmacology Studies n=245 • ONC201 was well tolerated at various dose levels (125 mg to 750 mg). • The majority of treatment-related adverse events across the clinical pharmacology studies were Grade 1 (mild) and transient. • Most common treatment-related AEs were grade 1 nausea and diz
Slide 11: Dordaviprone Phase 3 ACTION Study Summary
Dordaviprone Phase 3 ACTION Study Summary
Slide 12: Pivotal Phase 3 ACTION trial design
12 Now enrolling, a randomized, double-blind, placebo-controlled, multicenter international study in 450 newly diagnosed diffuse glioma patients whose tumor harbors an H3 K27M-mutation. Pivotal Phase 3 ACTION trial design 1. Excludes DIPG and spinal tumors • H3 K27M-mutant diffuse glioma1 • Radiatio
Slide 13: Design provides multiple paths for success
13 Design provides multiple paths for success Interim data expected in third quarter of 2025 Second OS Interim • ~246 events • Success at HR~0.64 Final OS • ~327 events • Success at HR~0.73 PFS by RANO HGG(2) • ~286 events • Success at HR~0.68 1. Overall Survival (OS) 2. Progression-free survival (P
Slide 14: Dordaviprone Market Opportunity Assessment
Dordaviprone Market Opportunity Assessment
Slide 15: (1) Ostrom QT, et al. Neuro Oncol. 2022;24(Suppl 5):v1-v95; (2) Patient numbers and percentages
15 (1) Ostrom QT, et al. Neuro Oncol. 2022;24(Suppl 5):v1-v95; (2) Patient numbers and percentages are estimates (weighted avg per sample size) derived from a review of the literature from (2012-2023): (Aihara K, et al. Neuro Oncol. 2014;16(1):140-6; Feng J, et al. Hum Pathol. 2015;46(11):1626-32; S
Slide 16: H3 K27M-mutant glioma: rapid ramp to peak revenue expected
16 • No approved therapies for H3 K27M mutant glioma, dordaviprone is the leading program targeting this mutation globally • Potential market opportunity ~$750 million • Approximately 5,000 patients in top seven markets1 • Ultra-orphan indication drug pricing • H3 K27M mutations most often in childr
Slide 17: Potential for imipridones beyond brain tumors
17 Potential for imipridones beyond brain tumors • Single agent responses in Ph 2 neuroendocrine trial of dordaviprone observed in subset (PC-PG) • PC-PG are adrenal-related tumors with elevated DRD2 expression • Five patients have been treated > 1 year • Fewer short-term and potential long-term tox
Slide 18: Dordaviprone Mechanism of Action
Dordaviprone Mechanism of ActionDordaviprone Mechanism of Action
Slide 19: Dordaviprone directly engages DRD2 and ClpP
19 • Dordaviprone can selectively induce apoptosis in cancer cells by altering the activity of two protein targets • DRD2 antagonism - DRD2 is a G protein-coupled neuroreceptor that regulates Ras signaling - Dordaviprone antagonizes DRD2, inhibiting Ras signaling pathways • ClpP agonism - ClpP norma
Slide 20: Mechanism and frontline clinical efficacy in H3 K27M DMG
20 Mechanism and frontline clinical efficacy in H3 K27M DMG Mitochondrial effects reverse H3 K27me3-loss hallmark of H3 K27M H3 K27me3-loss reversal evident in ONC201- treated H3 K27M patients Front-line ONC201 following RT survival benefit Increased confidence in Ph3 dose Provides ClpP connection t
Slide 21: ONC206
ONC206
Slide 22: ONC206: oral brain penetrant ClpP agonist + DRD2 antagonist
22 • Second generation imipridone • 10x higher in vitro potency relative to dordaviprone • Monotherapy efficacy across multiple preclinical models of CNS and non-CNS tumors • Tumor regression in patient-derived xenografts • Oral dose escalation trials with intensified dosing are ongoing in CNS cance
Slide 23: ONC206 Phase 1 dose escalation and intensification
23 ONC206 Phase 1 dose escalation and intensification to expected therapeutic range in CNS cancer patients1,2 Expect to complete enrollment of dose escalation in 2024 1. In partnership with Nation al Institutes of Health (NIH) 2. In partnership with Pacific Pediatric Neuro-Oncology Consortium (PNOC)
Slide 24: ONC206 is well-tolerated in adult and pediatric patients
24 ONC206 is well-tolerated in adult and pediatric patients 1. Adverse Events. Data extraction from Adult study and Pediatric study (PNOC Arms A and D) as of July2024 Related AEs1 Integrated Data Set N=77 All grades Grade ≥ 3 Any Treatment-related AE 60% 5% Fatigue 26% 1% Lymphocyte count decreased
Slide 25: ONC206 dose escalation and increased dose frequency well-tolerated
25 50mg QW N=10 100mg QW N=11 150mg QW N=11 200mg QW N=11 250mg QW N=10 350 mg QW N=33 50mg BID; TIW N=9 150mg QD; TIW N=9 100mg BID; TIW N=33 150mg BID; TIW 200mg BID; TIW Weekly Dosing Multi-day/ week dosing Weekly Dose 2 50 mg 100 mg 150 mg 200 mg 250 mg 350 mg 300 mg 450 mg 600 mg 900 mg 1200mg
Slide 26: ONC206 patient exposures exceed exposures associated with nonclinical efficacy
26 ONC206 patient exposures with intensified dosing exceed exposures associated with nonclinical efficacy 1. PK summary based on adult data; pediatric PK in DL 1-7 have been similar to adult 2. Average IC50 of 562 nM across 1088 cancer cell lines representing 25 tumor types 3. In vivo models include
Slide 27: ONC206 Mechanism of Action
ONC206 Mechanism of Action
Slide 28: ONC206 is a second generation dual ClpP agonist/DRD2 antagonist
28 • ClpP and DRD2 are direct binding targets that control mitochondrial and prosurvival functions, respectively, in a range of human cancers • ClpP agonism and DRD2 antagonism occurs at nanomolar concentrations • Anti-cancer activity is dependent on ClpP and/or DRD2 depending on tumor type • Downst
Slide 29: ONC206 exhibits monotherapy activity in multiple CNS cancer models
29 • Nanomolar activity across CNS tumors, including high-grade glioma and medulloblastoma • In vitro and in vivo data demonstrates enhanced efficacy with increasing dose and sustained exposure • Tumor regression and survival extension in transgenic and patient-derived medulloblastoma models ONC206
Slide 30: ONC206 shows monotherapy efficacy and tolerability in non-CNS solid tumors
30 • Broadly active across 1088 cancer cell lines representing 25 tumor types with an average IC50 of 562 nM 1 • In vivo efficacy improves with dose intensification in chemo-refractory TNBC, including tumor regressions2 • Improved efficacy relative to ONC201 in endometrial cancer3 ONC206 shows monot
Slide 31: Ongoing pipeline development
31 1. Rapidly Emerging Antiviral Drug Development Initiative Ongoing pipeline development • ONC212 GPR132 + ClpP agonist - GLP-tox studies complete, potential to advance to IND, work performed with support from academic grants - Preclinical studies are ongoing to evaluate additional oncology indicat
Slide 32: Corporate Update
Corporate Update
Slide 33: TEMBEXA deal term summary
33 Emergent BioSolutions is an experienced biodefense company collaborating with government agencies to protect public health Terms summary: • $238 million received upfront at closing in Q3 2022 • Up to an additional $124 million in potential BARDA procurement milestones • 20% royalty on future U.S.
Slide 34: Investment highlights and key catalysts
34 Investment highlights and key catalysts Dordaviprone Ph 3 trial enrolling - interim OS data expected in third quarter 2025 First-Line H3 K27M-mutant diffuse glioma – The ACTION Study No approved therapies targeting H3 K27M diffuse glioma, an area of high unmet medical need First in class mech
Slide 35: Chimerix
Chimerix Corporate Presentation